title: Pediatric lupus nephritis: more options, more chances?
abstract: Lupus nephritis (LN) is more common and severe in childhood-onset systemic lupus erythematosus (SLE) than in adults. It is one of the major causes of acute kidney injury (AKI) and chronic kidney disease (CKD) in children. Steroid therapy has been used as the first-line treatment for SLE since 1970, and has improved the survival of SLE patients from ∼ 50% to >80%. Over the years many immunosuppressive drugs, including pulse methylprednisolone, oral cyclophosphamide, pulse intravenous cyclophosphamide, mycophenolate mofitil, rituximab, and tacrolimus, have been combined with prednisolone, further improving survival rates to 90%-95%. However, the effectiveness of these drugs is still uncertain, as most seem very good in the beginning, but in studies examining longer-term follow-up the remission of disease does not remain. Fatal infection is still a major complication of aggressive chemotherapy, and the potential benefits as well as adverse events from each drug need to be considered. Induction of remission is the major aim of therapy, with safe and effective maintenance therapy for long-term remission. The survival rates of many published studies vary widely because of differences in patients and treatment modalities, severity of disease, renal histopathology, racial factors, and duration of follow-up. Finding the optimal treatment for SLE and related co-morbidities is highly challenging, and will likely involve a complex combination of different drugs for different patients in the search for giving them an opportunity to be free from this debilitating disease.
authors: Department of Pediatrics, Prince of Songkla University, Songkla 90110,Thailand. vprayong@gmail.com
authors: P
authors: P
authors: Vachvanichsanong
authors: E
authors: E
authors: McNeil
mesh_terms: D000328:Adult; D017668:Age of Onset; D002648:Child; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000188:drug therapy; D008181:Lupus Nephritis / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D012074:Remission Induction / Q000379:methods; D012720:Severity of Illness Index; D015996:Survival Rate
chemical_list: D005938:Glucocorticoids; D007166:Immunosuppressive Agents
keywords: Cyclophosphamide; lupus nephritis; mycophenolate mofetil; systemic lupus erythematosus (SLE); therapy